Brief: Cabaletta Bio Outlines Strategic Priorities And Anticipated Key Milestones For 2025
Cabaletta Bio Inc reports results for the quarter - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 60 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Duolingo, Nova, Universal Health Services
Cabaletta Bio Inc reports results for the quarter ended in January - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 55 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
Cabaletta Bio Inc reports results for the quarter ended in March - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 48 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Cabaletta Bio Announces FDA Granted Orphan Drug Designation To CABA-201 For Treatment Of Myositis
Cabaletta Bio rises on FDA's 'orphan drug' tag for cell therapy
Brief: Cabaletta Bio Unaudited Cash, Cash Equivalents And Short-Term Investments As Of Dec. 31, 2023 Was $241 Mln
Brief: Cabaletta Bio Receives Additional FDA Fast Track Designations For Caba-201 In Dermatomyositis And Systemic Sclerosis
U.S. RESEARCH ROUNDUP-Caredx, Ebix, Vera Therapeutics
Brief: Cabaletta Bio - Cash, Cash Equivalents And Short-Term Investments Expected To Support Operations Into Q4 2025
Brief: Cellares, Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201
Brief: Cabaletta Bio Receives FDA Clearance Of CABA-201 IND Application For Treatment Of Generalized Myasthenia Gravis
Brief: Cabaletta Bio And Wuxi Advanced Therapies Announce Expansion Of Gmp Manufacturing Agreement To Include Caba-201